Pub Date : 2022-07-26DOI: 10.2174/1573394718666220726105843
Mohammad Samare-Najaf, F. Zal, N. Jamali, S. Vakili, Z. Khodabandeh
In recent decades, the exposure to doxorubicin (DOX) has elevated due to the increment in the incidence of cancer, especially among the young population, which, despite the desired restorative impacts, threatened the quality of life of survivors, particularly concerning their reproductive ability. Although previous studies have shown the effectiveness of quercetin (QCT) and vitamin E (Vit.E), two major dietary antioxidants with favorable attributes regarding the female reproductive system, on doxorubicin-induced insulting to the ovary and uterus. The mechanisms involved in responding to stress and inflammation have not been elucidated. Hence, this study sought to evaluate the preventive effects of these two antioxidants on doxorubicin-induced disruption of ovarian and uterine stress and inflammation. The study involved 48 female rats that were equally allocated into 6 groups as control (CON), QCT (20mg/Kg), Vit.E (200mg/Kg), DOX (accumulative 15mg/Kg), DOX+QCT, and DOX+Vit.E. Upon 21 days treatment, the activity of Superoxide Dismutase (SOD), Catalase (CAT), Glutathione-dependent system, Total Antioxidant Capacity (1), Malondialdehyde (MDA), Nitric Oxide (NO), and Tumor Necrosis Factor-alpha (TNF-αin the reproductive tissues and serum were evaluated. Findings demonstrated that the levels of CAT, SOD, Glutathione Peroxidase (GPx), and TAC were alleviated by the studied antioxidants in both tissues (p-value<0.05). Furthermore, both supplements revealed ameliorative effects on DOX-induced alterations in NO, MDA (p-value<0.001), and TNF-αlevels. Taking together, the present findings suggested the promising alleviative properties of QCT and Vit.E via modulating stress- and inflammation-responsive mechanisms against DOX-induced female reproductive toxicity.
{"title":"Do Quercetin And Vitamin E Properties Preclude Doxorubicin-Induced Stress and Inflammation In Reproductive Tissues?","authors":"Mohammad Samare-Najaf, F. Zal, N. Jamali, S. Vakili, Z. Khodabandeh","doi":"10.2174/1573394718666220726105843","DOIUrl":"https://doi.org/10.2174/1573394718666220726105843","url":null,"abstract":"\u0000\u0000In recent decades, the exposure to doxorubicin (DOX) has elevated due to the increment in the incidence of cancer, especially among the young population, which, despite the desired restorative impacts, threatened the quality of life of survivors, particularly concerning their reproductive ability.\u0000\u0000\u0000\u0000Although previous studies have shown the effectiveness of quercetin (QCT) and vitamin E (Vit.E), two major dietary antioxidants with favorable attributes regarding the female reproductive system, on doxorubicin-induced insulting to the ovary and uterus. The mechanisms involved in responding to stress and inflammation have not been elucidated. Hence, this study sought to evaluate the preventive effects of these two antioxidants on doxorubicin-induced disruption of ovarian and uterine stress and inflammation.\u0000\u0000\u0000\u0000The study involved 48 female rats that were equally allocated into 6 groups as control (CON), QCT (20mg/Kg), Vit.E (200mg/Kg), DOX (accumulative 15mg/Kg), DOX+QCT, and DOX+Vit.E. Upon 21 days treatment, the activity of Superoxide Dismutase (SOD), Catalase (CAT), Glutathione-dependent system, Total Antioxidant Capacity (1), Malondialdehyde (MDA), Nitric Oxide (NO), and Tumor Necrosis Factor-alpha (TNF-αin the reproductive tissues and serum were evaluated.\u0000\u0000\u0000\u0000Findings demonstrated that the levels of CAT, SOD, Glutathione Peroxidase (GPx), and TAC were alleviated by the studied antioxidants in both tissues (p-value<0.05). Furthermore, both supplements revealed ameliorative effects on DOX-induced alterations in NO, MDA (p-value<0.001), and TNF-αlevels.\u0000\u0000\u0000\u0000Taking together, the present findings suggested the promising alleviative properties of QCT and Vit.E via modulating stress- and inflammation-responsive mechanisms against DOX-induced female reproductive toxicity.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42841662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-20DOI: 10.2174/1573394718666220720103303
L. Geranpayeh, E. Rahimpour
Breast cancer is relatively rare in men; however, the overall prevalence of breast cancer in men is steadily increasing. Due to the increasing prevalence of the disease, the final consequences of these patients have become more important. One of the major adverse outcomes in surviving patients is secondary cancer following primary breast cancer. The aim of this study was to evaluate the second cancer in men who have survived primary breast cancer. The risk of developing primary second cancers is higher in men with primary breast cancer than in women. Few studies have evaluated the risk of secondary cancers, other than breast cancer, in men with breast cancer. Men who had a history of breast cancer are 10 to 20 times more likely to develop second breast cancer than women, which increases with aging. The association of prostate and breast cancer in the family has been suggested in specific populations, and some studies have shown an increase in prostate cancer in men surviving breast cancer. Lung cancer has also increased in men after breast cancer, but the risk is lower than in women, which is affected by age and gender survival. Melanoma is the second cancer in older survivor men of certain races after one year of follow-up. Gastric cancer after breast cancer showed an increasing prevalence in younger men and surviving more than ten years and familial accumulation of cancer. Pancreatic cancer also increased in men with a family history of breast cancer and mutated genes after primary breast cancer. The risk of second cancer in men with primary breast cancer, like the first cancer, is multifactorial, and genetic and environmental factors can influence its prevalence. Therefore, more extensive research is needed to better understanding of interrelationship of etiological factors and to provide screening and early detection strategies in affected men.
{"title":"Second Cancer after Breast Cancer in Men","authors":"L. Geranpayeh, E. Rahimpour","doi":"10.2174/1573394718666220720103303","DOIUrl":"https://doi.org/10.2174/1573394718666220720103303","url":null,"abstract":"\u0000\u0000Breast cancer is relatively rare in men; however, the overall prevalence of breast cancer in men is steadily increasing. Due to the increasing prevalence of the disease, the final consequences of these patients have become more important. One of the major adverse outcomes in surviving patients is secondary cancer following primary breast cancer. The aim of this study was to evaluate the second cancer in men who have survived primary breast cancer. The risk of developing primary second cancers is higher in men with primary breast cancer than in women. Few studies have evaluated the risk of secondary cancers, other than breast cancer, in men with breast cancer. Men who had a history of breast cancer are 10 to 20 times more likely to develop second breast cancer than women, which increases with aging. The association of prostate and breast cancer in the family has been suggested in specific populations, and some studies have shown an increase in prostate cancer in men surviving breast cancer. Lung cancer has also increased in men after breast cancer, but the risk is lower than in women, which is affected by age and gender survival. Melanoma is the second cancer in older survivor men of certain races after one year of follow-up. Gastric cancer after breast cancer showed an increasing prevalence in younger men and surviving more than ten years and familial accumulation of cancer. Pancreatic cancer also increased in men with a family history of breast cancer and mutated genes after primary breast cancer. The risk of second cancer in men with primary breast cancer, like the first cancer, is multifactorial, and genetic and environmental factors can influence its prevalence. Therefore, more extensive research is needed to better understanding of interrelationship of etiological factors and to provide screening and early detection strategies in affected men.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47562047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-07DOI: 10.2174/1573394718666220707112238
Laaya Rostami, H. Soltanzadeh, Farzad Arjomandi Rad
Colorectal cancer (CC) is a common cancer in human and one of the major cause of cancer death worldwide. Recently, several therapeutic methods of CC and other malignancies have been developed, but drugs resistance is an important problem in treatment cancer treatment. Therefore, identify and provide novel chemotherapeutic agents is important for treatment of malignancies. In the present study we investigated the anti-cancer activity of Cuminum cyminum extraction in combination of layered double hydroxide (LDH) nanosheets on SW480 CC cell line. The anti-cancer activity of C. cyminum extraction and LDH nanosheets were investigated on SW480 CC cell line by MTT assay. The mRNA expression of apoptosis-related genes (BAX and BCL2) were investigated by Real-Time PCR method. Our results revealed that extraction of C. cyminum significantly decreased proliferation and viability of SW480 CC cell line as a concentration‐time dependent manner. However, anti-proliferation effects of C. cyminum extraction by co-administration of LDH nanosheets was significantly more than its monotherapy. Moreover, expression of BAX and BCL2 genes in the treated SW480 cells was significantly upregulated and downregulated, respectively. In general, present study revealed a significant anti-cancer effects of C. cyminum extraction and LDH nanosheets combination on SW480 CC cells, which may be due to apoptosis induction.
{"title":"Anti-proliferative effects of Cuminum cyminum extraction by co-administration of layered double hydroxide (LDH) nanosheets on SW480 colorectal cancer cell line through apoptosis induction","authors":"Laaya Rostami, H. Soltanzadeh, Farzad Arjomandi Rad","doi":"10.2174/1573394718666220707112238","DOIUrl":"https://doi.org/10.2174/1573394718666220707112238","url":null,"abstract":"\u0000\u0000Colorectal cancer (CC) is a common cancer in human and one of the major cause of cancer death worldwide. Recently, several therapeutic methods of CC and other malignancies have been developed, but drugs resistance is an important problem in treatment cancer treatment. Therefore, identify and provide novel chemotherapeutic agents is important for treatment of malignancies.\u0000\u0000\u0000\u0000In the present study we investigated the anti-cancer activity of Cuminum cyminum extraction in combination of layered double hydroxide (LDH) nanosheets on SW480 CC cell line.\u0000\u0000\u0000\u0000The anti-cancer activity of C. cyminum extraction and LDH nanosheets were investigated on SW480 CC cell line by MTT assay. The mRNA expression of apoptosis-related genes (BAX and BCL2) were investigated by Real-Time PCR method.\u0000\u0000\u0000\u0000Our results revealed that extraction of C. cyminum significantly decreased proliferation and viability of SW480 CC cell line as a concentration‐time dependent manner. However, anti-proliferation effects of C. cyminum extraction by co-administration of LDH nanosheets was significantly more than its monotherapy. Moreover, expression of BAX and BCL2 genes in the treated SW480 cells was significantly upregulated and downregulated, respectively.\u0000\u0000\u0000\u0000In general, present study revealed a significant anti-cancer effects of C. cyminum extraction and LDH nanosheets combination on SW480 CC cells, which may be due to apoptosis induction.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43667133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.2174/1573394718666220701123434
Huseyin Taskiran, Ataman Gonel
It has been shown that some drugs used for parenteral affect biochemical measurements. Anti-inflammatory and analgesic drugs may also have the potential to affect measurement methods. To investigate the effects of seven different anti-inflammatory and analgesic pharmacological agents commonly used in wards and intensive care units on thyroglobulin, CA125, CA15-3, CA19-9, CEA, PSA and total HCG tests measured by immunoassay technique. The study was performed using by hormone control material (BioRad Lyphocheck Immunoassay Plus Control) in the PETINIA immunoassay method (Siemens, Atellica, USA). 20 µL of Tenoxicam, Dexamethasone, methylprednisolone, paracetamol, diclofenac sodium, dexketoprofen, metamizole sodium were added into 180 µL of the control solution respectively. After vortexing the sample, it was incubated for 20 minutes at room temperature. Thyroglobulin, CA125, CA15-3, CA19-9, CEA, total PSA and total HCG tests were studied from the control sample. The study was re-performed by adding 20 µL of distilled water. The measurements were repeated 3 times and the mean values were recorded. Percentage deviation rates from the target value were calculated. Metamizole sodium led to negative interference in the CA 19-9, total HCG, CA 125, CEA, total PSA and CA15-3 at rate of -42.1%, -24.62%, -24.34%, -23.66%, -14.33%, -13.91%, respectively. With the administration of metamizole sodium, the only positive interference was determined at rate of 6.02% in thyroglobulin. Paracetamol-induced, the maximum deviation was calculated at the rate of -26.41% in CA 19-9. CA 19-9 deviated -12.22% from diclofenac sodium and -22.41% from dexketoprofen. With methylprednisolone administration, positive interference was detected at a rate of 14.46% in thyroglobulin and negative interference at a rate of -12% in total PSA. The highest deviation due to dexketoprofen was seen in CA 19-9 at rate of -22.41%. This study demonstrated the potential of anti-inflammatory, analgesic, and antipyretic agents to affect tumor marker measurements. Especially in the follow-up of cancer patients, anti-inflammatory interference may increase the likelihood of malpractice by causing erroneous clinical evaluations.
已经表明，一些用于胃肠外的药物会影响生化测量。抗炎和镇痛药物也可能影响测量方法。研究病房和重症监护室常用的七种不同抗炎镇痛药物对免疫测定法测定的甲状腺球蛋白、CA125、CA15-3、CA19-9、CEA、PSA和总HCG的影响。本研究使用PETINIA免疫测定法（Siemens，Atellica，USA）中的激素对照材料（BioRad-Lyphocheck Immunoassay Plus control）进行。将20µL的替诺昔康、地塞米松、甲基强的松龙、对乙酰氨基酚、双氯芬酸钠、右酮洛芬、安乃近钠分别加入180µL的对照溶液中。涡旋样品后，将其在室温下孵育20分钟。从对照样品中研究甲状腺球蛋白、CA125、CA15-3、CA19-9、CEA、总PSA和总HCG测试。通过添加20µL蒸馏水重新进行研究。重复测量3次，并记录平均值。计算了与目标值的百分比偏差率。异咪唑钠对CA19-9、总HCG、CA125、CEA、总PSA和CA15-3的负干扰率分别为-42.1%、-24.62%、-24.34%、-23.66%、-14.33%和-13.91%。安乃近钠给药后，甲状腺球蛋白中唯一的阳性干扰率为6.02%。在CA 19-9中，对乙酰氨基酚诱导的最大偏差计算为-26.41%。CA 19-9与双氯芬酸钠的偏差为-12.22%，与右酮洛芬的偏差为-22.41%。甲基强的松龙给药后，甲状腺球蛋白阳性干扰率为14.46%，总PSA阴性干扰率为-12%。右酮洛芬引起的最大偏差出现在CA 19-9中，发生率为-22.41%。本研究证明了抗炎、镇痛和解热药物对肿瘤标志物测量的影响。特别是在癌症患者的随访中，抗炎干预可能会导致错误的临床评估，从而增加医疗事故的可能性。
{"title":"In-Vitro Investigation of the Effect of Anti-Inflammatory and Analgesics on Measurement of Tumor Markers","authors":"Huseyin Taskiran, Ataman Gonel","doi":"10.2174/1573394718666220701123434","DOIUrl":"https://doi.org/10.2174/1573394718666220701123434","url":null,"abstract":"\u0000\u0000It has been shown that some drugs used for parenteral affect biochemical measurements. Anti-inflammatory and analgesic drugs may also have the potential to affect measurement methods.\u0000\u0000\u0000\u0000To investigate the effects of seven different anti-inflammatory and analgesic pharmacological agents commonly used in wards and intensive care units on thyroglobulin, CA125, CA15-3, CA19-9, CEA, PSA and total HCG tests measured by immunoassay technique.\u0000\u0000\u0000\u0000The study was performed using by hormone control material (BioRad Lyphocheck Immunoassay Plus Control) in the PETINIA immunoassay method (Siemens, Atellica, USA). 20 µL of Tenoxicam, Dexamethasone, methylprednisolone, paracetamol, diclofenac sodium, dexketoprofen, metamizole sodium were added into 180 µL of the control solution respectively. After vortexing the sample, it was incubated for 20 minutes at room temperature. Thyroglobulin, CA125, CA15-3, CA19-9, CEA, total PSA and total HCG tests were studied from the control sample. The study was re-performed by adding 20 µL of distilled water. The measurements were repeated 3 times and the mean values were recorded. Percentage deviation rates from the target value were calculated.\u0000\u0000\u0000\u0000Metamizole sodium led to negative interference in the CA 19-9, total HCG, CA 125, CEA, total PSA and CA15-3 at rate of -42.1%, -24.62%, -24.34%, -23.66%, -14.33%, -13.91%, respectively. With the administration of metamizole sodium, the only positive interference was determined at rate of 6.02% in thyroglobulin. Paracetamol-induced, the maximum deviation was calculated at the rate of -26.41% in CA 19-9. CA 19-9 deviated -12.22% from diclofenac sodium and -22.41% from dexketoprofen. With methylprednisolone administration, positive interference was detected at a rate of 14.46% in thyroglobulin and negative interference at a rate of -12% in total PSA. The highest deviation due to dexketoprofen was seen in CA 19-9 at rate of -22.41%.\u0000\u0000\u0000\u0000This study demonstrated the potential of anti-inflammatory, analgesic, and antipyretic agents to affect tumor marker measurements. Especially in the follow-up of cancer patients, anti-inflammatory interference may increase the likelihood of malpractice by causing erroneous clinical evaluations.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44520141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-10DOI: 10.2174/1573394718666220610185525
Anju M George, A. M A, Sharon K Joseph, A. Philip, R. Reghu, Krupa Merin Sam
In spite of the high efficacy rate of paclitaxel, physicians are compelled to discontinue the regimen due to its prevailing neurotoxicity and myelosuppressive effects, thus not being able to achieve the desired clinical outcomes. The neurotoxicity studies of paclitaxel have been mostly done on upper dose limits (>275mg/m2), and little information is available on lower doses. Since there is a lack of such studies in the Indian population, the medical professionals are unable to analyze at what cumulative dose does paclitaxel show maximum severity of peripheral neuropathy. This is a prospective observational study conducted for a period of 1 year in patients undergoing paclitaxel therapy. These patients were evaluated for the incidence and severity of paclitaxel induced peripheral neuropathy during the first 6 cycles using the QLQ-CIPN questionnaire. We also identified the cumulative dose at which most patients developed peripheral neuropathy and each patient’s quality of life using EORTC QLQ C30. Out of 85 patients, 76 developed peripheral neuropathy during the first 6 cycles. It was observed that the severity of peripheral neuropathy was increasing in each cycle of therapy. The overall quality of life of patients was decreasing with therapy, and at a cumulative dose of 525mg/m2 most of the patients (40%) developed symptoms of peripheral neuropathy. The incidence and severity of peripheral neuropathy increased with each cycle, and this has led to a significant reduction in the quality of life of patients post 6 cycles; and also, a high cumulative dose may limit the paclitaxel therapy.
{"title":"A prospective study on the incidence and severity of paclitaxel induced peripheral neuropathy in indian population","authors":"Anju M George, A. M A, Sharon K Joseph, A. Philip, R. Reghu, Krupa Merin Sam","doi":"10.2174/1573394718666220610185525","DOIUrl":"https://doi.org/10.2174/1573394718666220610185525","url":null,"abstract":"\u0000\u0000In spite of the high efficacy rate of paclitaxel, physicians are compelled to discontinue the regimen due to its prevailing neurotoxicity and myelosuppressive effects, thus not being able to achieve the desired clinical outcomes. The neurotoxicity studies of paclitaxel have been mostly done on upper dose limits (>275mg/m2), and little information is available on lower doses. Since there is a lack of such studies in the Indian population, the medical professionals are unable to analyze at what cumulative dose does paclitaxel show maximum severity of peripheral neuropathy.\u0000\u0000\u0000\u0000This is a prospective observational study conducted for a period of 1 year in patients undergoing paclitaxel therapy. These patients were evaluated for the incidence and severity of paclitaxel induced peripheral neuropathy during the first 6 cycles using the QLQ-CIPN questionnaire. We also identified the cumulative dose at which most patients developed peripheral neuropathy and each patient’s quality of life using EORTC QLQ C30.\u0000\u0000\u0000\u0000Out of 85 patients, 76 developed peripheral neuropathy during the first 6 cycles. It was observed that the severity of peripheral neuropathy was increasing in each cycle of therapy. The overall quality of life of patients was decreasing with therapy, and at a cumulative dose of 525mg/m2 most of the patients (40%) developed symptoms of peripheral neuropathy.\u0000\u0000\u0000\u0000The incidence and severity of peripheral neuropathy increased with each cycle, and this has led to a significant reduction in the quality of life of patients post 6 cycles; and also, a high cumulative dose may limit the paclitaxel therapy.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41955622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-03DOI: 10.2174/1573394718666220603103458
Harshad S Kapare, Srishti Nagaraj, Shweta Wakalkar, Karishma Rathi
Currently, synthetic therapeutic drugs used in cancer treatment are targeting cancerous tissues that also affect noncancerous dividing cells, which exhibit side effects that decrease the immune response, and affect quality of life. Traditional/ natural products are well proven for a variety of therapeutically active chemical constituents. Caffeic acid phenethyl ester (CAPE) is one of the bioactive molecules found in the natural product propolis is now attracting researcher’s interest because of its anticancer potential. The aim of this review is to summarize and critically analyze the current evidence on the therapeutic effects of CAPE in various types of cancer cells both in terms of in vitro and in vivo along with supportive anti-inflammatory & antioxidant activity in cancer therapy. This study focused on the mechanism pathways, synergism of CAPE. Various conventional and advanced targeted nanotechnology based formulation approaches developed for the delivery of CAPE as a promising therapeutic agent were also discussed in detail in terms of challenges and future opportunities. Overall study summarized and demonstrated the excellent therapeutic potential, mechanisms, and formulation approaches of CAPE as a therapeutic bioactive molecule. Study and research further can be initiated for the investigation of biopharmaceutical aspects for therapeutic and clinical applications
{"title":"Caffeic acid phenethyl ester: a potential anticancer bioactive constituent of propolis.","authors":"Harshad S Kapare, Srishti Nagaraj, Shweta Wakalkar, Karishma Rathi","doi":"10.2174/1573394718666220603103458","DOIUrl":"https://doi.org/10.2174/1573394718666220603103458","url":null,"abstract":"\u0000\u0000Currently, synthetic therapeutic drugs used in cancer treatment are targeting cancerous tissues that also affect noncancerous dividing cells, which exhibit side effects that decrease the immune response, and affect quality of life. Traditional/ natural products are well proven for a variety of therapeutically active chemical constituents. Caffeic acid phenethyl ester (CAPE) is one of the bioactive molecules found in the natural product propolis is now attracting researcher’s interest because of its anticancer potential.\u0000\u0000\u0000\u0000The aim of this review is to summarize and critically analyze the current evidence on the therapeutic effects of CAPE in various types of cancer cells both in terms of in vitro and in vivo along with supportive anti-inflammatory & antioxidant activity in cancer therapy.\u0000\u0000\u0000\u0000This study focused on the mechanism pathways, synergism of CAPE. Various conventional and advanced targeted nanotechnology based formulation approaches developed for the delivery of CAPE as a promising therapeutic agent were also discussed in detail in terms of challenges and future opportunities.\u0000\u0000\u0000\u0000Overall study summarized and demonstrated the excellent therapeutic potential, mechanisms, and formulation approaches of CAPE as a therapeutic bioactive molecule. Study and research further can be initiated for the investigation of biopharmaceutical aspects for therapeutic and clinical applications\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43642653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-01DOI: 10.2174/1573394718666220601124415
Tien Van Le, Erica L. Kim, Tracy Togba-Bass, Joyce Edlyne Chima Bom, R. B. Campbell
According to the American Cancer Society, the prevalence of lymphoma remains high in the United States with an estimated 90,390 new cases, and 21,680 deaths annually. Although current chemotherapeutic regimens approved by the FDA can effectively improve treatment outcomes, the prognosis remains poor with numerous complications. Current therapeutic strategies have faced multiple challenges limiting desired therapeutic effects. With the multitude of clinical barriers faced by conventional treatment strategies, researchers continue to explore the use of nanotherapeutics over more conventional treatment options. The engineered nanoparticles include starting materials from a number of biocompatible sources, and the final products can safely incorporate therapeutic agents, improve drug selectivity to tumor targets, and enhance efficacy profiles, all while reducing toxicity associated with the drug payload. These are tremendous potential advantages. This review summarizes the molecular basis of lymphoma, disease progression, and therapeutic challenges encountered during treatment. The discussions further highlight preclinical and clinical results at the different clinical stages, reviewing the different types of lymphoma, and summarizing how nanotherapeutics have addressed challenges confronting treatment.
{"title":"Therapeutic Management of Lymphoma: Conventional Strategies and Overcoming Treatment Barriers with Nanotherapeutics.","authors":"Tien Van Le, Erica L. Kim, Tracy Togba-Bass, Joyce Edlyne Chima Bom, R. B. Campbell","doi":"10.2174/1573394718666220601124415","DOIUrl":"https://doi.org/10.2174/1573394718666220601124415","url":null,"abstract":"\u0000\u0000According to the American Cancer Society, the prevalence of lymphoma remains high in the United States with an estimated 90,390 new cases, and 21,680 deaths annually. Although current chemotherapeutic regimens approved by the FDA can effectively improve treatment outcomes, the prognosis remains poor with numerous complications. Current therapeutic strategies have faced multiple challenges limiting desired therapeutic effects. With the multitude of clinical barriers faced by conventional treatment strategies, researchers continue to explore the use of nanotherapeutics over more conventional treatment options. The engineered nanoparticles include starting materials from a number of biocompatible sources, and the final products can safely incorporate therapeutic agents, improve drug selectivity to tumor targets, and enhance efficacy profiles, all while reducing toxicity associated with the drug payload. These are tremendous potential advantages. This review summarizes the molecular basis of lymphoma, disease progression, and therapeutic challenges encountered during treatment. The discussions further highlight preclinical and clinical results at the different clinical stages, reviewing the different types of lymphoma, and summarizing how nanotherapeutics have addressed challenges confronting treatment.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47195463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-19DOI: 10.2174/1573394718666220519115626
Z. Farzaneh, M. Farzaneh
Hepatocellular carcinoma (HCC) is the second malignancy worldwide. Dysregulation of various signaling pathways has been detected in HCC. Recent investigations have suggested a new approach for the prevention and treatment of HCC with herbal drugs. The anticancer effects of herbal drugs can be evaluated in animal models or HCC cell lines. Various molecular mechanisms and signaling pathways such as TGF-β, Wnt/β-catenin, SHH, Notch, Hippo, PI3K, and VEGF have been found to induce and promote carcinogenesis of HCC. Herbal drugs can target the signaling pathways in HCC and trigger apoptosis, suppress proliferation, and tumor growth. Molecularly targeted therapies using herbal drugs can be novel therapeutic strategies against HCC. This study provides the latest findings on using herbal medicine-derived compounds in the control of HCC.
{"title":"Herbal medicine-derived compounds for the prevention and treatment of hepatocellular carcinoma..","authors":"Z. Farzaneh, M. Farzaneh","doi":"10.2174/1573394718666220519115626","DOIUrl":"https://doi.org/10.2174/1573394718666220519115626","url":null,"abstract":"\u0000\u0000Hepatocellular carcinoma (HCC) is the second malignancy worldwide. Dysregulation of various signaling pathways has been detected in HCC. Recent investigations have suggested a new approach for the prevention and treatment of HCC with herbal drugs. The anticancer effects of herbal drugs can be evaluated in animal models or HCC cell lines. Various molecular mechanisms and signaling pathways such as TGF-β, Wnt/β-catenin, SHH, Notch, Hippo, PI3K, and VEGF have been found to induce and promote carcinogenesis of HCC. Herbal drugs can target the signaling pathways in HCC and trigger apoptosis, suppress proliferation, and tumor growth. Molecularly targeted therapies using herbal drugs can be novel therapeutic strategies against HCC. This study provides the latest findings on using herbal medicine-derived compounds in the control of HCC.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45103494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-17DOI: 10.2174/1573394718666220517112049
D. Majumder
This article is aimed to understand the gradual development of cancer systems medicine and how this provides a better therapeutic strategy (in terms of drug selection, dose and duration) and patients care. Hence, this study is focused to understand the need and the evolving nature of the analytical models for the assessment of the outcome of different cancer therapeutics. Presently, cancer is viewed from a quantitative standpoint; hence, several analytical models on different cancers have developed. From the information of cancer development to therapeutic advantage, mathematical oncology has contributed significantly. With a fewer number of variables, models in this area have successfully synchronized the model output with real-life dynamical data. However, with the availability of large scale data for different cancers, systems biology has gained importance. It provides biomedical insights among a large number of variables. And to get information for clinically relevant variables especially, the controlling variable(s), cancer systems medicine is suggested. In this article, we have reviewed the gradual development of the field from mathematical oncology to cancer systems biology to cancer systems medicine. An intensive search with PubMed, IEEE Xplorer and Google for cancer model, analytical model and cancer systems biology was made and the latest developments have been noted. Gradual development of cancer systems biology entails the importance of the development of models towards a unified model of cancer treatment. For this, the model should be flexible so that different types of cancer and/or its therapy can be included within the same model. With the existing knowledge, relevant variables are included in the same model, followed by simulation studies that will enrich the knowledge base further. Such a deductive approach in the modelling and simulations efforts can help to tackle the adversity of individual cancer cases in future. This approach is indeed important to encompass the fourth industrial revolution in health sector. Towards the development of a unified modelling effort, a multi-scale modelling approach could be suitable; so that different researchers across the globe can add their contribution to enrich the same model. Moreover, with this, the identification of controlling variables may be possible. Towards this goal, middle-out rationalist approach (MORA) is working on analytical models for cancer treatment.
{"title":"Mathematical Oncology to Cancer Systems Medicine: Translation from Academic Pursuit to Individualized Therapy with MORA","authors":"D. Majumder","doi":"10.2174/1573394718666220517112049","DOIUrl":"https://doi.org/10.2174/1573394718666220517112049","url":null,"abstract":"\u0000\u0000This article is aimed to understand the gradual development of cancer systems medicine and how this provides a better therapeutic strategy (in terms of drug selection, dose and duration) and patients care. Hence, this study is focused to understand the need and the evolving nature of the analytical models for the assessment of the outcome of different cancer therapeutics.\u0000\u0000\u0000\u0000Presently, cancer is viewed from a quantitative standpoint; hence, several analytical models on different cancers have developed. From the information of cancer development to therapeutic advantage, mathematical oncology has contributed significantly. With a fewer number of variables, models in this area have successfully synchronized the model output with real-life dynamical data. However, with the availability of large scale data for different cancers, systems biology has gained importance. It provides biomedical insights among a large number of variables. And to get information for clinically relevant variables especially, the controlling variable(s), cancer systems medicine is suggested.\u0000\u0000\u0000\u0000In this article, we have reviewed the gradual development of the field from mathematical oncology to cancer systems biology to cancer systems medicine. An intensive search with PubMed, IEEE Xplorer and Google for cancer model, analytical model and cancer systems biology was made and the latest developments have been noted.\u0000\u0000\u0000\u0000Gradual development of cancer systems biology entails the importance of the development of models towards a unified model of cancer treatment. For this, the model should be flexible so that different types of cancer and/or its therapy can be included within the same model. With the existing knowledge, relevant variables are included in the same model, followed by simulation studies that will enrich the knowledge base further. Such a deductive approach in the modelling and simulations efforts can help to tackle the adversity of individual cancer cases in future. This approach is indeed important to encompass the fourth industrial revolution in health sector.\u0000\u0000\u0000\u0000Towards the development of a unified modelling effort, a multi-scale modelling approach could be suitable; so that different researchers across the globe can add their contribution to enrich the same model. Moreover, with this, the identification of controlling variables may be possible. Towards this goal, middle-out rationalist approach (MORA) is working on analytical models for cancer treatment.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46439518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-13DOI: 10.2174/1573394718666220513115452
Anggia Prameswari Wardhana, T. Nurseta, Mukhammad Nooryanto
Cervical cancer is the second most common cancer found in pregnant women at a young age. Neoadjuvant with carboplatin and paclitaxel is often given to patients with cervical cancer, but the experience of administration during pregnancy is very limited. A 22-year-old woman was diagnosed with stage IIA2 cervical cancer at 26 weeks gestation. Patients received three medications, including neoadjuvant chemotherapy, carboplatin, paclitaxel, in three cycles with three weeks intervals at 27 weeks gestation. The patient underwent a pregnancy termination with emergency cesarean delivery at 36 weeks of gestation and continued with a hysterectomy radical 60 days, after which the patient received a chemoradiation adjuvant. Mother and baby are healthy one year after diagnosis. Neoadjuvant chemotherapy with carboplatin and paclitaxel can prevent progression of the disease and is safe for pregnant women and fetal in early stage cervical cancer in young age continued with delay radical hysterectomy.
{"title":"Neoadjuvant Chemotherapy, Carboplatin, and Paclitaxel in Pregnancy of a 22-Year Old with Stage IIA2 Cervical Cancer","authors":"Anggia Prameswari Wardhana, T. Nurseta, Mukhammad Nooryanto","doi":"10.2174/1573394718666220513115452","DOIUrl":"https://doi.org/10.2174/1573394718666220513115452","url":null,"abstract":"\u0000\u0000Cervical cancer is the second most common cancer found in pregnant women at a young age. Neoadjuvant with carboplatin and paclitaxel is often given to patients with cervical cancer, but the experience of administration during pregnancy is very limited.\u0000\u0000\u0000\u0000A 22-year-old woman was diagnosed with stage IIA2 cervical cancer at 26 weeks gestation. Patients received three medications, including neoadjuvant chemotherapy, carboplatin, paclitaxel, in three cycles with three weeks intervals at 27 weeks gestation. The patient underwent a pregnancy termination with emergency cesarean delivery at 36 weeks of gestation and continued with a hysterectomy radical 60 days, after which the patient received a chemoradiation adjuvant. Mother and baby are healthy one year after diagnosis.\u0000\u0000\u0000\u0000Neoadjuvant chemotherapy with carboplatin and paclitaxel can prevent progression of the disease and is safe for pregnant women and fetal in early stage cervical cancer in young age continued with delay radical hysterectomy.\u0000","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2022-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43008393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：